|
US6764697B1
(en)
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
|
US5160742A
(en)
*
|
1991-12-31 |
1992-11-03 |
Abbott Laboratories |
System for delivering an active substance for sustained release
|
|
IT1260505B
(it)
*
|
1992-06-01 |
1996-04-09 |
Poli Ind Chimica Spa |
Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
|
|
FR2692484B1
(fr)
*
|
1992-06-22 |
1995-06-30 |
Gouchet Franck |
Nouvelle forme galenique de 4-asa a liberation controlee.
|
|
WO1995016451A1
(fr)
*
|
1992-06-22 |
1995-06-22 |
Franck Arno Gouchet |
Comprimes a liberation controlee de 4-asa
|
|
AU670958B2
(en)
*
|
1992-08-05 |
1996-08-08 |
Mayne Pharma International Pty Ltd |
Pelletised pharmaceutical composition
|
|
NZ253999A
(en)
*
|
1992-08-05 |
1996-07-26 |
Faulding F H & Co Ltd |
Pelletised substained release medicament
|
|
US5358502A
(en)
|
1993-02-25 |
1994-10-25 |
Pfizer Inc |
PH-triggered osmotic bursting delivery devices
|
|
US5914132A
(en)
*
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
IT1265092B1
(it)
*
|
1993-05-31 |
1996-10-30 |
Giuliani Spa |
Preparato per uso come integratore alimentare, o dietetico,a rilascio mirato nel colon
|
|
DE4332394A1
(de)
*
|
1993-09-23 |
1995-03-30 |
Falk Pharma Gmbh |
Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
|
|
US5536505A
(en)
*
|
1993-12-15 |
1996-07-16 |
Eastman Chemical Company |
Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
|
|
US5523095A
(en)
*
|
1993-12-15 |
1996-06-04 |
Eastman Chemical Company |
Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
|
|
JP3867171B2
(ja)
|
1994-04-22 |
2007-01-10 |
アステラス製薬株式会社 |
結腸特異的薬物放出システム
|
|
AT403988B
(de)
*
|
1994-05-18 |
1998-07-27 |
Lannacher Heilmittel |
Festes orales retardpräparat
|
|
US5686106A
(en)
*
|
1995-05-17 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form for colonic delivery
|
|
KR100598714B1
(ko)
*
|
1995-12-21 |
2006-07-10 |
파마슈티스크 라보라토리움 페링 에이/에스 |
5-아미노살리실산을 함유하는 방출 제어형 경구용 약제학적조성물 및 장 질환을 치료하는 방법
|
|
US5840332A
(en)
*
|
1996-01-18 |
1998-11-24 |
Perio Products Ltd. |
Gastrointestinal drug delivery system
|
|
US6245351B1
(en)
|
1996-03-07 |
2001-06-12 |
Takeda Chemical Industries, Ltd. |
Controlled-release composition
|
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
|
AUPO247496A0
(en)
|
1996-09-23 |
1996-10-17 |
Resmed Limited |
Assisted ventilation to match patient respiratory need
|
|
WO1998026767A2
(en)
*
|
1996-12-17 |
1998-06-25 |
Poli Industria Chimica S.P.A. |
Site-specific controlled release dosage formulation for mesalamine
|
|
AU5310898A
(en)
*
|
1996-12-20 |
1998-07-17 |
Dumex-Alpharma A/S |
Release-controlled coated tablets
|
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
|
US5788987A
(en)
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
|
DE19732903A1
(de)
|
1997-07-30 |
1999-02-04 |
Falk Pharma Gmbh |
Pellet-Formulierung zur Behandlung des Intestinaltraktes
|
|
DE59804823D1
(de)
*
|
1997-09-25 |
2002-08-22 |
Bayer Ag |
Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
|
|
US6974590B2
(en)
|
1998-03-27 |
2005-12-13 |
Cima Labs Inc. |
Sublingual buccal effervescent
|
|
US20030118645A1
(en)
*
|
1998-04-29 |
2003-06-26 |
Pather S. Indiran |
Pharmaceutical compositions for rectal and vaginal administration
|
|
US20030091629A1
(en)
*
|
1998-03-27 |
2003-05-15 |
Cima Labs Inc. |
Sublingual buccal effervescent
|
|
NZ513037A
(en)
|
1999-01-29 |
2003-05-30 |
Disphar Internat B |
Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
|
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
|
DK1183014T3
(da)
|
1999-06-14 |
2004-02-09 |
Cosmo Spa |
Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
|
|
US8895064B2
(en)
|
1999-06-14 |
2014-11-25 |
Cosmo Technologies Limited |
Controlled release and taste masking oral pharmaceutical composition
|
|
US6500462B1
(en)
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
|
US7897140B2
(en)
*
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
US6451345B1
(en)
|
2000-01-20 |
2002-09-17 |
Eurand Pharmaceuticals Ltd. |
Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
|
|
US6627223B2
(en)
*
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
|
IT1318625B1
(it)
*
|
2000-07-14 |
2003-08-27 |
Roberto Valducci |
Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
|
|
AU2001284434A1
(en)
|
2000-09-06 |
2002-03-22 |
Mitsubishi Pharma Corporation |
Granular preparations for oral administration
|
|
CA2359812C
(en)
*
|
2000-11-20 |
2004-02-10 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
|
|
US6932861B2
(en)
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
|
US6699315B2
(en)
|
2000-11-28 |
2004-03-02 |
Fmc Corporation |
Edible PGA coating composition
|
|
EP1368000A4
(en)
|
2001-03-13 |
2004-12-01 |
Penwest Pharmaceuticals Co |
CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID
|
|
KR20010069756A
(ko)
*
|
2001-05-08 |
2001-07-25 |
유형선 |
소염진통제인 아세메타신을 함유하며 장관내 특히대장에서의 약물 방출 속도가 조절되는 약물 전달 체계에대한 약제학적 경구용 조성물 및 그에 대한 제조방법
|
|
US20030068356A1
(en)
*
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
|
US6500454B1
(en)
*
|
2001-10-04 |
2002-12-31 |
Eurand Pharmaceuticals Ltd. |
Timed, sustained release systems for propranolol
|
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
|
AR036797A1
(es)
|
2001-10-15 |
2004-10-06 |
Ferring Bv |
Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
|
|
WO2003032916A2
(en)
*
|
2001-10-16 |
2003-04-24 |
Structural Bioinformatics Inc. |
Organosulfur inhibitors of tyrosine phosphatases
|
|
NZ532564A
(en)
*
|
2001-11-23 |
2006-06-30 |
Procter & Gamble |
Solid unit dosage forms for oral administration which minimise the impact of coating fractures especially for larger or heavier dosage forms
|
|
JP2005516020A
(ja)
*
|
2001-12-20 |
2005-06-02 |
ファルマシア・コーポレーション |
ゼロ次持続放出剤形およびその製造方法
|
|
US8829198B2
(en)
*
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
|
AU2003248747A1
(en)
|
2002-06-27 |
2004-01-19 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
|
EP1606291A2
(en)
*
|
2002-07-02 |
2005-12-21 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its dervatives
|
|
GB0217056D0
(en)
*
|
2002-07-23 |
2002-08-28 |
Ass Octel |
Use
|
|
US7799752B2
(en)
|
2002-08-14 |
2010-09-21 |
Quest International Services B.V. |
Compositions comprising encapsulated material
|
|
EP1393706A1
(en)
*
|
2002-08-14 |
2004-03-03 |
Quest International B.V. |
Fragranced compositions comprising encapsulated material
|
|
AU2003284942A1
(en)
*
|
2002-10-30 |
2004-06-07 |
Pharmacia Corporation |
Oral extended release tablets and methods of making and using the same
|
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
|
TWI355276B
(en)
*
|
2003-01-14 |
2012-01-01 |
Akira Tsuji |
Gastrointestinal absorption enhancer mediated by p
|
|
BRPI0408805A
(pt)
*
|
2003-03-31 |
2006-03-28 |
Pliva Lachema As |
composição farmacêutica contendo complexo de platina e método de fabricação da mesma
|
|
CA2520197A1
(en)
|
2003-04-23 |
2004-11-04 |
Ferring B.V. |
Sachet for a pharmaceutical composition
|
|
WO2004099158A1
(en)
*
|
2003-04-30 |
2004-11-18 |
Ricerca Biosciences, Llc. |
Monocyclic diazodioxide based bcl-2 protein antagonists
|
|
WO2004099162A1
(en)
*
|
2003-04-30 |
2004-11-18 |
Ricerca Biosciences, Llc. |
Polycyclic diazodioxide-based bcl-2 protein antagonist
|
|
WO2004110350A2
(en)
*
|
2003-05-14 |
2004-12-23 |
Torreypines Therapeutics, Inc. |
Compouds and uses thereof in modulating amyloid beta
|
|
US8916598B2
(en)
|
2003-05-30 |
2014-12-23 |
Proteotech Inc |
Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
|
|
US20100331380A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Esposito Luke A |
Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
|
|
US7057100B2
(en)
*
|
2003-06-26 |
2006-06-06 |
The J.C. Robinson Seed Co. |
Inbred corn line W23129
|
|
EP2112920B1
(en)
|
2003-06-26 |
2018-07-25 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
|
US7825106B2
(en)
|
2003-09-03 |
2010-11-02 |
Agi Therapeutics Ltd. |
Modified release formulations and methods of treating inflammatory bowel disease
|
|
US7737133B2
(en)
|
2003-09-03 |
2010-06-15 |
Agi Therapeutics Ltd. |
Formulations and methods of treating inflammatory bowel disease
|
|
EA200600598A1
(ru)
|
2003-09-19 |
2006-08-25 |
Пенвест Фармасьютикалз Ко. |
Лекарственные формы замедленного высвобождения
|
|
US7410978B2
(en)
|
2003-11-04 |
2008-08-12 |
Supernus Pharmaceuticals, Inc. |
Once daily dosage forms of trospium
|
|
AU2004289222B2
(en)
|
2003-11-04 |
2010-01-21 |
Supernus Pharmaceuticals Inc. |
Compositions of quaternary ammonium containing bioavailability enhancers
|
|
EP1547601A1
(en)
|
2003-12-23 |
2005-06-29 |
Ferring B.V. |
Coating method
|
|
US7858121B2
(en)
|
2003-12-31 |
2010-12-28 |
Cima Labs, Inc. |
Effervescent oral fentanyl dosage form and methods of administering fentanyl
|
|
AU2004311879B2
(en)
*
|
2003-12-31 |
2010-08-05 |
Phoenix Labs Unlimited Company |
Effervescent oral opiate dosage form
|
|
CN102078310B
(zh)
*
|
2003-12-31 |
2013-01-23 |
奇马实验室公司 |
大体线性的泡腾口服芬太尼剂型和施用方法
|
|
US7670624B2
(en)
|
2004-01-29 |
2010-03-02 |
Astella Pharma Inc. |
Gastrointestinal-specific multiple drug release system
|
|
WO2005090370A1
(en)
*
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
|
JP2005272347A
(ja)
*
|
2004-03-24 |
2005-10-06 |
Ohara Yakuhin Kogyo Kk |
固形製剤の製造方法
|
|
WO2005113523A1
(en)
|
2004-05-20 |
2005-12-01 |
Foldrx Pharmaceuticals, Inc. |
2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
|
|
EP1768668A2
(en)
|
2004-06-16 |
2007-04-04 |
Tap Pharmaceutical Products, Inc. |
Multiple ppi dosage form
|
|
US20060135773A1
(en)
*
|
2004-06-17 |
2006-06-22 |
Semple Joseph E |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
|
EP1786421A2
(en)
*
|
2004-07-09 |
2007-05-23 |
Cengent Therapeutics, Inc. |
Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
|
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
|
WO2006028970A1
(en)
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
|
CA2580767A1
(en)
|
2004-09-17 |
2006-03-30 |
Whitehead Institute For Biomedical Research |
Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
|
|
US20060067889A1
(en)
*
|
2004-09-27 |
2006-03-30 |
Light Sciences Corporation |
Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
|
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
|
NZ589750A
(en)
|
2004-10-21 |
2012-07-27 |
Aptalis Pharmatech Inc |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
|
US9149439B2
(en)
|
2005-03-21 |
2015-10-06 |
Sandoz Ag |
Multi-particulate, modified-release composition
|
|
EP1866319B1
(en)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
|
WO2008051197A2
(en)
*
|
2005-09-20 |
2008-05-02 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
|
WO2007106537A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Activx Biosciences, Inc. |
Aminoquinolones as gsk-3 inhibitors
|
|
EA200870385A1
(ru)
*
|
2006-03-29 |
2009-04-28 |
Фолдркс Фармасьютикалз, Инк. |
Ингибирование токсичности альфа-синуклеина
|
|
WO2007112581A1
(en)
*
|
2006-04-03 |
2007-10-11 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
|
MX2009001248A
(es)
|
2006-08-03 |
2009-02-11 |
Nitec Pharma Ag |
Tratamiento con glucocorticoide de liberacion prolongada de enfermedad reumatoide.
|
|
EP2484696B1
(en)
|
2006-08-28 |
2017-08-16 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic hLIGHT-specific human monoclonal antibodies
|
|
BRPI0716481A2
(pt)
*
|
2006-09-04 |
2014-03-18 |
Panacea Biotec Ltd |
Tecnologia de liberação flutuante programável
|
|
CA2664152C
(en)
|
2006-09-21 |
2014-09-30 |
Activx Biosciences, Inc. |
Serine hydrolase inhibitors
|
|
BRPI0715579A2
(pt)
|
2006-10-19 |
2015-05-26 |
Auspex Pharmaceuticals Inc |
"composto, composição farmacêutica e uso de um composto"
|
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
|
AU2007333667A1
(en)
|
2006-12-19 |
2008-06-26 |
Auspex Pharmaceuticals, Inc. |
Preperation and utility of CCR5 inhibitors
|
|
WO2008079371A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of c3a receptor and methods of use thereof
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
AU2008219622A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
|
|
LT2125698T
(lt)
|
2007-03-15 |
2016-10-10 |
Auspex Pharmaceuticals, Inc. |
Deuterintas d9-venlafaksinas
|
|
US9114238B2
(en)
|
2007-04-16 |
2015-08-25 |
Corium International, Inc. |
Solvent-cast microprotrusion arrays containing active ingredient
|
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
|
US9597293B2
(en)
*
|
2007-05-07 |
2017-03-21 |
Evonik Röhm Gmbh |
Solid dosage forms comprising an enteric coating with accelerated drug release
|
|
EP2170062A4
(en)
*
|
2007-07-12 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
|
|
WO2009035634A2
(en)
*
|
2007-09-11 |
2009-03-19 |
Activx Biosciences, Inc. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
|
|
CN101855229A
(zh)
|
2007-09-12 |
2010-10-06 |
埃迪威克斯生物科学公司 |
作为gsk-3抑制剂的螺环状氨基喹诺酮
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
WO2009048607A1
(en)
|
2007-10-10 |
2009-04-16 |
Corium International, Inc. |
Vaccine delivery via microneedle arrays
|
|
BRPI0818286A2
(pt)
*
|
2007-10-12 |
2020-08-11 |
Takeda Pharmaceuticals North America, Inc. |
métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
|
|
US8802156B2
(en)
|
2007-11-14 |
2014-08-12 |
Laboratorios Farmacéuticos Rovi, S.A. |
Pharmaceutical forms for the release of active compounds
|
|
WO2009066152A2
(en)
|
2007-11-21 |
2009-05-28 |
Pharmaxis Ltd. |
Haloallylamine inhibitors of ssao/vap-1 and uses therefor
|
|
WO2009111611A2
(en)
*
|
2008-03-05 |
2009-09-11 |
Proteotech Inc. |
Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
|
|
KR101713501B1
(ko)
|
2008-03-17 |
2017-03-07 |
암비트 바이오사이언시즈 코포레이션 |
Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
|
|
US20120034155A1
(en)
*
|
2010-08-03 |
2012-02-09 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Artificial cells
|
|
CN101658533A
(zh)
*
|
2008-08-29 |
2010-03-03 |
首都医科大学宣武医院 |
抗肿瘤药物的干细胞递送
|
|
CA2739465C
(en)
|
2008-10-03 |
2017-01-31 |
Dr. Falk Pharma Gmbh |
Compositions and methods for the treatment of bowel diseases with granulated mesalamine
|
|
RS56049B1
(sr)
|
2008-11-13 |
2017-09-29 |
Nogra Pharma Ltd |
Antisens kompozicije i postupci za pripremu i upotrebu istih
|
|
TWI494108B
(zh)
*
|
2009-01-26 |
2015-08-01 |
Nitec Pharma Ag |
糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
|
|
NZ582836A
(en)
*
|
2009-01-30 |
2011-06-30 |
Nitec Pharma Ag |
Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
RU2529019C2
(ru)
|
2009-02-27 |
2014-09-27 |
Эмбит Байосайенсиз Корпорейшн |
Модулирующие jak киназу хиназолиновые производные и способы их применения
|
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス，インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
|
|
MX2011009413A
(es)
|
2009-03-11 |
2011-10-21 |
Ambit Biosciences Corp |
Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
|
|
KR101748891B1
(ko)
*
|
2009-03-11 |
2017-06-19 |
교린 세이야꾸 가부시키 가이샤 |
Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
|
|
JP5766177B2
(ja)
|
2009-03-27 |
2015-08-19 |
ベトディーシー，インコーポレイテッド |
ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
KR20120034627A
(ko)
|
2009-04-22 |
2012-04-12 |
액시킨 파마수티컬스 인코포레이티드 |
아릴설폰아마이드 ｃｃｒ3 길항제
|
|
BRPI1014669A2
(pt)
|
2009-04-22 |
2017-07-18 |
Axikin Pharmaceuticals Inc |
antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída
|
|
NZ620048A
(en)
|
2009-04-22 |
2015-07-31 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
|
EP2532659A1
(en)
|
2009-07-07 |
2012-12-12 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
DK2451435T4
(da)
|
2009-07-08 |
2022-02-28 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Natriumthiosulfat-indeholdende farmaceutiske sammensætninger
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
|
CN102470127A
(zh)
|
2009-08-19 |
2012-05-23 |
埃姆比特生物科学公司 |
联芳基化合物和其使用方法
|
|
US8470817B2
(en)
*
|
2009-10-26 |
2013-06-25 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
US8871460B2
(en)
|
2009-11-09 |
2014-10-28 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
CN102958515A
(zh)
|
2009-12-02 |
2013-03-06 |
阿普塔利斯制药有限公司 |
非索非那定微胶囊及含有非索非那定微胶囊的组合物
|
|
CA2784748A1
(en)
|
2009-12-18 |
2011-06-23 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
|
HRP20160834T1
(hr)
|
2010-02-23 |
2016-09-23 |
Da Volterra |
Formulacije za oralnu dopremu adsorbensa u crijevo
|
|
US8999995B2
(en)
|
2010-03-02 |
2015-04-07 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
US8741894B2
(en)
|
2010-03-17 |
2014-06-03 |
Axikin Pharmaceuticals, Inc. |
Arylsulfonamide CCR3 antagonists
|
|
US9687641B2
(en)
|
2010-05-04 |
2017-06-27 |
Corium International, Inc. |
Method and device for transdermal delivery of parathyroid hormone using a microprojection array
|
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
|
US20130178503A1
(en)
|
2010-06-01 |
2013-07-11 |
Biotheryx Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
|
|
JP5844354B2
(ja)
|
2010-06-01 |
2016-01-13 |
ビオトヘルイク， インコーポレイテッド |
ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
|
|
EP2576532B1
(en)
|
2010-06-07 |
2018-07-18 |
Novomedix, LLC |
Furanyl compounds and the use thereof
|
|
US20130178522A1
(en)
|
2010-07-19 |
2013-07-11 |
James M. Jamison |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
EP2611796B1
(en)
|
2010-09-01 |
2016-04-20 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
EP2611794A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
JP5872558B2
(ja)
|
2010-09-01 |
2016-03-01 |
アムビト ビオスシエンセス コルポラチオン |
ピラゾリルアミノキナゾリンの臭化水素酸塩
|
|
WO2012030918A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
EP2611809A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
US20130225615A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
WO2012030912A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
|
CA2810024A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
EP2611812A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
US20120088769A1
(en)
|
2010-10-11 |
2012-04-12 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
|
EP3178465A1
(en)
|
2010-12-06 |
2017-06-14 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
AR085091A1
(es)
|
2011-01-26 |
2013-09-11 |
Kolltan Pharmaceuticals Inc |
Anticuerpos anti-kit y sus usos
|
|
EP2670396A1
(en)
|
2011-01-31 |
2013-12-11 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
|
JP6042406B2
(ja)
|
2011-03-28 |
2016-12-14 |
メイ プハルマ，インコーポレーテッド |
（α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
|
|
EP2691388A1
(en)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
BR112013024909A2
(pt)
|
2011-03-28 |
2019-09-24 |
Mei Pharma Inc |
composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
JP5813391B2
(ja)
*
|
2011-06-24 |
2015-11-17 |
日東電工株式会社 |
粒子製剤の製造方法
|
|
RU2013158449A
(ru)
|
2011-06-23 |
2015-07-27 |
Мэп Фармасьютикалс, Инк. |
Новые фторэрголиновые аналоги
|
|
US10154964B2
(en)
|
2011-09-07 |
2018-12-18 |
Cosmo Technologies Limited |
Controlled release and taste masking oral pharmaceutical composition
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
IN2014CN03597A
(enExample)
|
2011-10-14 |
2015-10-09 |
Ambit Biosciences Corp |
|
|
EP2599477A1
(en)
|
2011-11-30 |
2013-06-05 |
Lunamed AG |
4-Phenylbutyric acid sustained release formulation
|
|
EP2793580A4
(en)
|
2011-12-19 |
2015-05-20 |
Map Pharmaceuticals Inc |
NEW DERIVATIVES OF ISO-ERGOLINE
|
|
AU2012355983A1
(en)
|
2011-12-21 |
2015-01-22 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
|
JP2012107058A
(ja)
*
|
2012-02-27 |
2012-06-07 |
Warner Chilcott Co Llc |
複数のコーティングを有する医薬剤形
|
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
US10071058B2
(en)
*
|
2012-03-07 |
2018-09-11 |
Santarus, Inc. |
Controlled-release solid dosage forms of mesalamine
|
|
SG11201405761WA
(en)
|
2012-03-16 |
2014-10-30 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
|
CA3008794C
(en)
|
2012-03-29 |
2021-03-16 |
Therabiome, Llc |
Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
|
|
CN104520268B
(zh)
|
2012-05-02 |
2017-05-24 |
勃林格殷格翰国际有限公司 |
Ssao的取代的3‑卤代烯丙基胺抑制剂及其用途
|
|
CN103417380B
(zh)
*
|
2012-05-22 |
2016-01-06 |
正和制药股份有限公司 |
具有肠溶膜衣的硬胶囊
|
|
EP2861562B1
(en)
|
2012-06-14 |
2018-05-09 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
SG11201500489YA
(en)
|
2012-07-25 |
2015-02-27 |
Kolltan Pharmaceuticals Inc |
Anti-kit antibodies and uses thereof
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
WO2014033077A1
(en)
|
2012-08-28 |
2014-03-06 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets
|
|
KR20150053906A
(ko)
|
2012-09-07 |
2015-05-19 |
액시킨 파마수티컬스 인코포레이티드 |
동위원소 농축 아릴설폰아미드 ccr3 길항제
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
EP2916830A2
(en)
|
2012-11-08 |
2015-09-16 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
US9156781B2
(en)
|
2012-11-30 |
2015-10-13 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
|
JP6865524B2
(ja)
|
2012-12-21 |
2021-04-28 |
コリウム， インコーポレイテッド |
治療剤を送達するためのマイクロアレイおよび使用方法
|
|
US9169214B2
(en)
|
2012-12-21 |
2015-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
|
|
US8895743B2
(en)
|
2012-12-21 |
2014-11-25 |
Map Pharmaceuticals, Inc. |
Methysergide derivatives
|
|
EP2943188A1
(en)
|
2013-01-11 |
2015-11-18 |
Mayo Foundation for Medical Education and Research |
Vitamins c and k for treating polycystic diseases
|
|
JP6487899B2
(ja)
|
2013-03-12 |
2019-03-20 |
コリウム インターナショナル， インコーポレイテッド |
微小突起アプリケータ
|
|
RU2015140610A
(ru)
|
2013-03-14 |
2017-04-17 |
ТЕРАБАЙОМ, ЭлЭлСи |
Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
|
|
WO2014144973A1
(en)
|
2013-03-15 |
2014-09-18 |
Corium International, Inc. |
Microarray for delivery of therapeutic agent, methods of use, and methods of making
|
|
AU2014237279B2
(en)
|
2013-03-15 |
2018-11-22 |
Corium Pharma Solutions, Inc. |
Microarray with polymer-free microstructures, methods of making, and methods of use
|
|
EP4059450A1
(en)
|
2013-03-15 |
2022-09-21 |
Corium, Inc. |
Microstructure array for delivery of active agents
|
|
WO2014150285A2
(en)
|
2013-03-15 |
2014-09-25 |
Corium International, Inc. |
Multiple impact microprojection applicators and methods of use
|
|
HK1218856A1
(zh)
|
2013-03-15 |
2017-03-17 |
Warner Chilcott Company, Llc |
用於减少递送变化性的具有多种剂量单元的美沙拉嗪药物组合物
|
|
EP2968118B1
(en)
|
2013-03-15 |
2022-02-09 |
Corium, Inc. |
Microarray for delivery of therapeutic agent and methods of use
|
|
SG11201509982UA
(enExample)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
RU2016111675A
(ru)
|
2013-08-30 |
2017-10-04 |
Эмбит Байосайенсиз Корпорейшн |
Соединения биарилацетамида и способы их применения
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015127351A1
(en)
|
2014-02-24 |
2015-08-27 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
US10202398B2
(en)
|
2014-03-20 |
2019-02-12 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
|
US10005765B2
(en)
|
2014-03-20 |
2018-06-26 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
|
AU2015259471A1
(en)
|
2014-05-12 |
2016-11-24 |
Conatus Pharmaceuticals, Inc. |
Treatment of the complications of chronic liver disease with caspase inhibitors
|
|
SMT202100116T1
(it)
|
2014-05-28 |
2021-05-07 |
Agenus Inc |
Anticorpi anti-gitr e metodi di utilizzo degli stessi
|
|
WO2015195474A1
(en)
|
2014-06-18 |
2015-12-23 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
EP3179857B1
(en)
|
2014-08-14 |
2021-09-08 |
Mamoun M. Alhamadsheh |
Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
|
|
WO2016033540A1
(en)
|
2014-08-29 |
2016-03-03 |
Corium International, Inc. |
Microstructure array for delivery of active agents
|
|
EP3188714A1
(en)
|
2014-09-04 |
2017-07-12 |
Corium International, Inc. |
Microstructure array, methods of making, and methods of use
|
|
CN106999593A
(zh)
|
2014-09-12 |
2017-08-01 |
妥必徕疗治公司 |
用于纤维化治疗的赛尼克韦罗组合疗法
|
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
EP3333191B1
(en)
|
2014-12-11 |
2020-09-09 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
|
WO2016106221A1
(en)
|
2014-12-22 |
2016-06-30 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
|
HUE049801T2
(hu)
|
2014-12-23 |
2020-10-28 |
Sma Therapeutics Inc |
3,5-diaminopirazol kináz inhibitorok
|
|
BR112017015487A2
(pt)
|
2015-01-20 |
2018-01-30 |
Xoc Pharmaceuticals Inc |
Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
|
|
CN107405346A
(zh)
|
2015-01-20 |
2017-11-28 |
Xoc制药股份有限公司 |
异麦角灵化合物及其用途
|
|
WO2016119700A1
(en)
|
2015-01-28 |
2016-08-04 |
Jn Therapeutics |
Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
|
|
ES2937020T3
(es)
|
2015-03-03 |
2023-03-23 |
Kymab Ltd |
Anticuerpos, usos y métodos
|
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
CN113713108A
(zh)
|
2015-06-23 |
2021-11-30 |
纽罗克里生物科学有限公司 |
用于治疗神经学疾病或病症的vmat2抑制剂
|
|
WO2017004067A1
(en)
|
2015-06-29 |
2017-01-05 |
Corium International, Inc. |
Microarray for delivery of therapeutic agent, methods of use, and methods of making
|
|
HK1257840A1
(zh)
|
2015-09-01 |
2019-11-01 |
Agenus Inc. |
抗-pd-1抗体及其使用方法
|
|
LT3875459T
(lt)
|
2015-10-30 |
2024-02-26 |
Neurocrine Biosciences, Inc. |
Valbenazino dihidrochlorido druskos ir jų polimorfai
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
EP4455145A3
(en)
|
2015-12-02 |
2025-03-12 |
Astraea Therapeutics, LLC |
Piperidinyl nociceptin receptor compounds
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
CA3009169A1
(en)
|
2015-12-23 |
2017-06-29 |
Neurocrine Biosciences, Inc. |
Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
|
|
JP2019500397A
(ja)
|
2015-12-31 |
2019-01-10 |
クオナトウス ファーマシューティカルズ，インコーポレイテッド |
カスパーゼ阻害剤を肝疾患の治療に使用する方法
|
|
KR20180099712A
(ko)
|
2016-01-08 |
2018-09-05 |
셀진 코포레이션 |
항증식성 화합물, 및 이의 약제학적 조성물 및 용도
|
|
AU2017206039B2
(en)
|
2016-01-08 |
2021-03-25 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-N-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
US10960013B2
(en)
|
2016-03-04 |
2021-03-30 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
JP2019510085A
(ja)
|
2016-03-08 |
2019-04-11 |
ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
癌治療のためのナノ粒子ならびに方法および化合物
|
|
JP2019513151A
(ja)
|
2016-03-08 |
2019-05-23 |
ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
カンプトテシン誘導体及びその使用
|
|
US11173135B2
(en)
|
2016-03-17 |
2021-11-16 |
Thiogenesis Therapeutics, Inc. |
Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
|
|
CN108884019A
(zh)
|
2016-04-11 |
2018-11-23 |
克雷西奥生物科技有限公司 |
氘代氯胺酮衍生物
|
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
|
BR112018071363A2
(pt)
*
|
2016-04-19 |
2019-02-05 |
Ferring Bv |
composições farmacêuticas orais de nicotinamida
|
|
EP3445340A1
(en)
*
|
2016-04-19 |
2019-02-27 |
Ferring B.V. |
Oral pharmaceutical compositions of mesalazine
|
|
WO2017194789A1
(en)
|
2016-05-13 |
2017-11-16 |
Institut Pasteur |
Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
MA45123A
(fr)
|
2016-05-27 |
2019-04-10 |
Agenus Inc |
Anticorps anti-tim-3 et leurs méthodes d'utilisation
|
|
CA3030099A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
WO2018035281A1
(en)
|
2016-08-17 |
2018-02-22 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
MA46285A
(fr)
|
2016-09-19 |
2019-07-31 |
Mei Pharma Inc |
Polythérapie
|
|
CA3037380A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
|
WO2018089427A1
(en)
|
2016-11-09 |
2018-05-17 |
Novomedix, Llc |
Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
WO2018102252A1
(en)
|
2016-11-30 |
2018-06-07 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
US10799503B2
(en)
|
2016-12-01 |
2020-10-13 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
|
JP2020500875A
(ja)
|
2016-12-02 |
2020-01-16 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
|
|
EP3551225A1
(en)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
FI3551660T3
(fi)
|
2016-12-07 |
2023-12-11 |
Agenus Inc |
Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
|
|
JP7090151B2
(ja)
|
2017-01-27 |
2022-06-23 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２インヒビターを投与するための方法
|
|
JP7307681B2
(ja)
|
2017-02-17 |
2023-07-12 |
カムリス インターナショナル インコーポレイテッド |
汎用性抗毒素
|
|
NZ797281A
(en)
|
2017-02-17 |
2025-10-31 |
Eidos Therapeutics Inc |
Processes for preparing ag-10, its intermediates, and salts thereof
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
KR20190133198A
(ko)
|
2017-03-27 |
2019-12-02 |
셀진 코포레이션 |
면역원성의 감소를 위한 방법 및 조성물
|
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
|
JP2020517242A
(ja)
|
2017-04-21 |
2020-06-18 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ＡｐｏＣ３抗体およびその使用方法
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
TW202402800A
(zh)
|
2017-05-01 |
2024-01-16 |
美商艾吉納斯公司 |
抗ｔｉｇｉｔ抗體類和使用彼等之方法
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
IL270654B2
(en)
*
|
2017-05-17 |
2024-07-01 |
Confluence Pharmaceuticals Llc |
Formulations of homotaurines and salts thereof
|
|
CA3064274A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
|
EP3645040A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
|
|
EP3645563A4
(en)
|
2017-06-27 |
2021-03-17 |
Neuracle Science Co., Ltd |
ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
|
|
EP3645039A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
|
|
US11746149B2
(en)
|
2017-06-27 |
2023-09-05 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
|
|
ES2953032T3
(es)
|
2017-09-01 |
2023-11-07 |
Univ East Carolina |
Métodos ex vivo para la activación de las células inmunológicas
|
|
EP3459528B1
(en)
*
|
2017-09-20 |
2022-11-23 |
Tillotts Pharma Ag |
Preparation of solid dosage forms comprising antibodies by solution/suspension layering
|
|
CN118924717A
(zh)
|
2017-09-20 |
2024-11-12 |
硫创治疗公司 |
用于治疗半胱胺敏感性病症的方法
|
|
MA50175B1
(fr)
|
2017-09-21 |
2025-05-30 |
Neurocrine Biosciences, Inc. |
Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
|
|
EP3692171A4
(en)
|
2017-10-02 |
2021-06-23 |
Neuracle Science Co., Ltd |
USING ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODIES FOR TREATMENT AND DIAGNOSIS OF MENTAL DISORDERS
|
|
EP3691658A4
(en)
|
2017-10-04 |
2021-06-23 |
The Regents of The University of California |
IMMUNOMODULATOR OLIGOSACCHARIDES
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
AU2017435893B2
(en)
|
2017-10-10 |
2023-06-29 |
Neurocrine Biosciences, Inc |
Methods for the administration of certain VMAT2 inhibitors
|
|
BR112020008514A2
(pt)
|
2017-10-31 |
2020-10-20 |
Staten Biotechnology B.V. |
anticorpos anti-apoc3 e métodos de uso dos mesmos
|
|
EP3501503A1
(en)
|
2017-12-22 |
2019-06-26 |
Cosmo Technologies Ltd. |
Solid delivery composition
|
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
JP7395480B2
(ja)
|
2018-01-10 |
2023-12-11 |
クラ セラピューティクス， エルエルシー |
フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
|
|
KR20200135996A
(ko)
|
2018-03-23 |
2020-12-04 |
에이도스 테라퓨틱스, 인코포레이티드 |
Ag10을 사용하여 ttr 아밀로이드증을 치료하는 방법
|
|
EP3823986A4
(en)
|
2018-04-24 |
2022-03-23 |
Neuracle Science Co., Ltd |
USE OF ANTIBODIES AGAINST FAMILY SEQUENCE 19, ITEM A5 IN THE TREATMENT OF NEUROPATHIC PAIN
|
|
CA3098807A1
(en)
|
2018-05-08 |
2019-11-14 |
Neuracle Science Co., Ltd. |
Adeno-associated virus (aav) delivery of anti-fam19a5 antibodies
|
|
AU2019265888A1
(en)
|
2018-05-10 |
2020-11-26 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
WO2019241555A1
(en)
|
2018-06-14 |
2019-12-19 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
|
CA3105352A1
(en)
|
2018-06-29 |
2020-01-02 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
CN118994395A
(zh)
|
2018-07-20 |
2024-11-22 |
皮埃尔法布雷医药公司 |
Vista受体
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
EP4647068A2
(en)
|
2018-08-17 |
2025-11-12 |
Eidos Therapeutics, Inc. |
Formulations of ag10
|
|
EP3860713A2
(en)
|
2018-10-03 |
2021-08-11 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
|
CN113166237B
(zh)
|
2018-10-16 |
2024-11-01 |
纽洛可科学有限公司 |
抗fam19a5抗体的用途
|
|
WO2020102728A1
(en)
|
2018-11-16 |
2020-05-22 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
|
IT201800011120A1
(it)
|
2018-12-14 |
2020-06-14 |
Dpl Pharma S P A |
Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
|
|
EP3898609A1
(en)
|
2018-12-19 |
2021-10-27 |
Shy Therapeutics LLC |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
KR102757347B1
(ko)
|
2018-12-27 |
2025-01-23 |
주식회사 뉴라클사이언스 |
죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용
|
|
JP2022515960A
(ja)
|
2019-01-02 |
2022-02-24 |
ニューラクル サイエンス カンパニー リミテッド |
抗配列類似性１９を持つファミリー、メンバーａ５抗体及びその使用方法
|
|
TWI839461B
(zh)
|
2019-02-06 |
2024-04-21 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
|
ES2978570T3
(es)
|
2019-02-26 |
2024-09-16 |
Inspirna Inc |
Anticuerpos anti-MERTK de alta afinidad y sus usos
|
|
ES2988904T3
(es)
|
2019-03-07 |
2024-11-22 |
Nobo Medicine Inc |
Inhibidores de caspasa y métodos de utilización de los mismos
|
|
ES3036313T3
(en)
|
2019-05-20 |
2025-09-17 |
Nirvana Sciences Inc |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
|
CN119752217A
(zh)
|
2019-05-20 |
2025-04-04 |
尼尔瓦纳科学股份有限公司 |
窄发射染料、包含其的组合物以及制备和使用其的方法
|
|
EP3996813A1
(en)
|
2019-07-11 |
2022-05-18 |
Cura Therapeutics, LLC |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
US20220274922A1
(en)
|
2019-07-11 |
2022-09-01 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2021030474A1
(en)
|
2019-08-12 |
2021-02-18 |
Massachusetts Institute Of Technology |
Articles and methods for administration of therapeutic agents
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
PH12022550460A1
(en)
|
2019-08-30 |
2023-02-27 |
Agenus Inc |
Anti-cd96 antibodies and methods of use thereof
|
|
WO2021055376A1
(en)
|
2019-09-16 |
2021-03-25 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
|
JP2023512456A
(ja)
|
2020-01-13 |
2023-03-27 |
ネオイミューンテック， インコーポレイテッド |
Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
|
|
WO2021151001A1
(en)
|
2020-01-22 |
2021-07-29 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
|
KR20220137630A
(ko)
|
2020-02-05 |
2022-10-12 |
워싱턴 유니버시티 |
Il-7 단백질과 car-보유 면역 세포의 조합물로 고형 종양을 치료하는 방법
|
|
US11529331B2
(en)
|
2020-05-29 |
2022-12-20 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
|
|
WO2021257828A1
(en)
|
2020-06-18 |
2021-12-23 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
US12024521B2
(en)
|
2020-06-30 |
2024-07-02 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
|
WO2022061348A1
(en)
|
2020-09-16 |
2022-03-24 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
TW202231269A
(zh)
|
2020-10-23 |
2022-08-16 |
美商拜歐斯瑞克斯公司 |
Kras蛋白降解劑、其醫藥組合物及其治療應用
|
|
WO2022094475A1
(en)
|
2020-11-02 |
2022-05-05 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
|
JP2023549112A
(ja)
|
2020-11-05 |
2023-11-22 |
ネオイミューンテック， インコーポレイテッド |
Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
|
|
KR20230157936A
(ko)
|
2020-12-14 |
2023-11-17 |
바이오테릭스, 인코포레이티드 |
Pde4 분해인자, 약제학적 조성물, 및 치료학적 적용
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
US20220280585A1
(en)
*
|
2021-03-05 |
2022-09-08 |
Poopermints, LLC |
Pharmaceutical composition containing champignon extract and peppermint and methods of use thereof
|
|
WO2022192545A1
(en)
|
2021-03-10 |
2022-09-15 |
Dice Molecules Sv, Inc. |
Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
|
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
JP2024520676A
(ja)
|
2021-06-02 |
2024-05-24 |
ライエル・イミュノファーマ・インコーポレイテッド |
Ｎｒ４ａ３欠損免疫細胞及びその使用
|
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Antibodies against interleukin 9 and methods of using them
|
|
WO2022266249A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
CA3222240A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2023055045A1
(ko)
|
2021-09-29 |
2023-04-06 |
주식회사 엔바이오스 |
코일드 코일 융합 단백질
|
|
CA3236150A1
(en)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
KR20240115979A
(ko)
|
2021-11-08 |
2024-07-26 |
프로젠토스 테라퓨틱스, 인크. |
혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
|
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
|
WO2023129576A2
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
AU2022441090A1
(en)
|
2022-02-17 |
2024-08-22 |
Novelty Nobility Inc. |
Antibody-drug conjugate.
|
|
CN118922189A
(zh)
|
2022-03-02 |
2024-11-08 |
线粒体能量有限公司 |
衍生自烟酸和核糖的新型前药
|
|
WO2023192904A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
US12187699B2
(en)
|
2022-04-14 |
2025-01-07 |
Bristol-Myers Squibb Company |
GSPT1 compounds and methods of use of the novel compounds
|
|
CN119095962A
(zh)
|
2022-05-05 |
2024-12-06 |
生物马林药物股份有限公司 |
治疗杜氏肌营养不良的方法
|
|
JP2025516555A
(ja)
|
2022-05-10 |
2025-05-30 |
バイオセリックス， インコーポレイテッド |
Ｃｄｋタンパク質分解因子、医薬組成物、及び治療応用
|
|
EP4525892A1
(en)
|
2022-05-19 |
2025-03-26 |
Lyell Immunopharma, Inc. |
Polynucleotides targeting nr4a3 and uses thereof
|
|
IL319458A
(en)
|
2022-09-09 |
2025-05-01 |
Innovo Therapeutics Inc |
Compounds that reduce ck1α and dual ck1α/gspt1
|
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
|
EP4604988A1
(en)
|
2022-10-21 |
2025-08-27 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
EP4608834A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing pyridine compounds
|
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
US20240174672A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridone Compounds
|
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
AU2024240129A1
(en)
|
2023-03-17 |
2025-10-09 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
US20240383990A1
(en)
|
2023-04-07 |
2024-11-21 |
Diagonal Therapeutics Inc. |
Hinge-modified bispecific antibodies
|
|
AU2024252640A1
(en)
|
2023-04-07 |
2025-10-02 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
|
|
WO2024226471A2
(en)
|
2023-04-24 |
2024-10-31 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating stxbp1 disorders
|
|
TW202448485A
(zh)
|
2023-05-05 |
2024-12-16 |
美商拜奧馬林製藥公司 |
肌萎縮蛋白外顯子跳躍寡核苷酸
|
|
WO2024233642A1
(en)
|
2023-05-09 |
2024-11-14 |
Progentos Therapeutics, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2024243048A1
(en)
|
2023-05-19 |
2024-11-28 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to il12 receptor
|
|
WO2025010272A1
(en)
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|
|
WO2025046298A2
(en)
|
2023-09-01 |
2025-03-06 |
iTeos Belgium SA |
Anti-trem2 antibodies and methods of use
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
TW202530223A
(zh)
|
2023-09-27 |
2025-08-01 |
美商艾索司特瑞克斯公司 |
Ｍｙｓｔ抑制劑
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
WO2025090519A1
(en)
|
2023-10-23 |
2025-05-01 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025133707A1
(en)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anti-tdp-43 antibodies and uses thereof
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025201633A1
(en)
|
2024-03-26 |
2025-10-02 |
Chen Gefei |
An agent for reducing amyloid formation
|